Novartis CEO, staring down $16.7B post-2030 patent cliff, challenges Wall Street consensus

NVS
Novartis CEO Vas Narasimhan challenged Wall Street analysts’ current consensus, which models the company’s 2035 sales at roughly $64 billion, a $20 billion gap from Novartis’ own projection. (Sedat Suna/Getty Images)

Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the upcoming U.S. generic entry for breast cancer blockbuster Kisqali prompted the Swiss drugmaker to trim its mid-term revenue outlook.

Unveiled at an investor event in London on Thursday, Novartis projected net sales to grow at a 5% compound annual rate in constant currencies between 2026 and 2031. That marks a slight step down from its prior guidance of 5% to 6% annual growth from 2025 through 2030. 

Speaking on a press call ahead of Thursday’s investor presentation, CEO Vas Narasimhan attributed the lower growth target to Kisqali’s looming loss of U.S. market exclusivity in the second half of 2031, based on its patent settlement agreements.

Kisqali is among three of Novartis’ largest current growth pillars—alongside Cosentyx and Kesimpta—that are projected to plunge from $23.9 billion sales in 2030 to just $7.2 billion in 2035, creating a $16.7 billion hole in Novartis’ top line. Kisqali is expected to suffer the biggest loss from $11 billion to $2.9 billion during the period. 

Cosentyx, currently Novartis’ top-selling drug, is expected to peak in 2027 before an Inflation Reduction Act-mandated price cut and the drug's loss of exclusivity hit, Narasimhan explained during the investor event. 

Even so, Narasimhan challenged Wall Street analysts’ current consensus, which models Novartis’ 2035 sales at roughly $64 billion, leaving an approximately $20 billion gap to reach the mid-single-digit growth that Novartis maintained on Thursday through the mid-2030s. And the chief executive insisted that most of the post-2031 growth will be coming from Novartis’ existing pipeline and brands, rather than M&A.

To build that longer-term momentum, Novartis is leaning on both newer commercial brands and promising pipeline candidates. 

After it recently raised the peak sales target for BTK inhibitor Rhapsido to above $8 billion across urticaria and relapsing multiple sclerosis (Novartis plans to introduce a new brand name for the drug in neuroscience indications), Novartis on Thursday also dialed up its peak sales guidance for Kesimpta (from $6 billion to $8 billion), Scemblix and Leqvio (each from $4 billion to $5 billion).

Narasimhan said the upgrades reflect commercial traction rather than new clinical data. These include Scemblix approaching 50% U.S. new-to-brand share in first-line chronic myeloid leukemia, while the PCSK9 drug Leqvio is getting a pre-filled syringe as Novartis accelerates work on an autoinjector.

Behind in-market assets, Narasimhan outlined more than 20 new molecules in phase 3 and phase 2 trials, including nine with multibillion-dollar peak sales potential.

He highlighted five core programs that are capable of generating the first $10 billion toward bridging the 2035 gap. Those include: Rhapsido, BAFF inhibitor and Sjögren's disease candidate ianalumab, BET inhibitor and myelofibrosis candidate pelabresib (for which Novartis is gearing up for a U.S. filing), Actinium-225 prostate cancer radioligand therapy Ac-PSMA-617, and Factor XI/XIa inhibitor abelacimab (targeting a 2028 approval filing in atrial fibrillation).

“If you’re missing $10 billion in 2035, and you can’t get there with the size of our pipeline, then your probabilities are wrong.” Narasimhan said. “They’re just wrong. It’s just unlikely that that’s going to be the case.”

He pointed to some other pipeline candidates, arguing that “it just takes two or three of these to hit, and you get there.”

He stressed that the compound growth rate is not for each year but an average number through 2035. 

While Novartis is proposing to keep its revenue trajectory based on its internal pipeline, the company remains active on the dealmaking front. But management suggested that most of the deals that Novartis strikes are simply too early-stage to move the needle for the midterm and would have “a marginal impact” for the 2031-2035 timeframe.

“The vast majority of our deal activity is in exploratory to preclinical,” Narasimhan said. “Most of the deals we do and we plan to do remain in the sub-$2 billion space.”

“We selectively do larger deals, but we believe that having that strategy consistently over time can generate big winners,” he added.

In addition to growing the top line, Novartis also aims for its core operating income margin to return to above 40% by 2029. 

Narasimhan noted that Novartis is evolving toward a 50-50-split between its U.S. and international businesses, which means lower profit margins compared with its Big Pharma peers with bigger U.S. contributions. He acknowledged that not having a megabrand would weigh on the margin but argued that diversification matters.

“You could argue from both a mission standpoint for Novartis, but also in terms of our profile,” Narasimhan said. “We’re more diversified. Diversify the risk, diversify as well in terms of pulling the margin down.”

By Novartis’ count, the Swiss pharma will have the most $5 billion-plus brands in the industry by the end of the decade, which Narasimhan said is better than spreading them out into many $2 billion-plus products in terms of business efficiency. 

“We do believe we can be in the 40s over time, but what we won’t ever want to do is compromise on the R&D investments,” Narasimhan said. “We want to main that 20%-plus R&D investment, and that has to be the core of the P&L in the long run.”